Improved local control of rectal cancer reduces distant metastases

被引:43
作者
Bernstein, T. E. [1 ]
Endreseth, B. H. [1 ,2 ]
Romundstad, P. [3 ]
Wibe, A. [1 ,2 ]
机构
[1] Univ Trondheim Hosp, St Olavs Hosp, Dept Surg, N-7006 Trondheim, Norway
[2] Norwegian Univ Sci & Technol, Dept Canc Res & Mol Med, N-7034 Trondheim, Norway
[3] Norwegian Univ Sci & Technol, Dept Publ Hlth, N-7034 Trondheim, Norway
关键词
Rectal cancer; national study; metastases; prognostic factors; CIRCUMFERENTIAL RESECTION MARGIN; COLORECTAL LIVER METASTASES; TOTAL MESORECTAL EXCISION; SURVIVAL; RADIOTHERAPY; SURGERY; CHEMORADIOTHERAPY; MANAGEMENT; RECURRENCE; NORWAY;
D O I
10.1111/j.1463-1318.2012.03089.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Aim The purpose of the present national study was to determine whether improved local control has been accompanied by a change in the incidence of metastases. Method The data were from a national population-based rectal cancer registry and included all 6501 rectal cancer patients treated for cure. The study periods were 19931997, 19982000, 20012003 and 20042006. Results Major changes in the handling of rectal cancer from the first to the last study period included an increased use of MRI from zero to 81% and the use of preoperative radiotherapy from 5% to 20%. The proportion of patients with circumferential resection margin (CRM) = 2 mm decreased from 23% to 13%. The 4-year rate of local recurrence decreased from 13% to 8% (P < 0.001), the overall survival increased from 65% to 73% (P < 0.001) and the incidence of distant metastases decreased from 25% to 19% (P < 0.001) from the first to the last period. The risk of metastases decreased by 29% (hazard ratio 0.71, 95% CI 0.600.84). Conclusion Improved diagnostics and treatment of rectal cancer aiming at better local control and survival have resulted in a significant reduction in the incidence of distant metastases.
引用
收藏
页码:E668 / E678
页数:11
相关论文
共 22 条
[1]  
Adam R, 2004, ANN SURG, V240, P644, DOI 10.1097/01.sla.0000141198.92114.16
[2]  
Adam R, 2001, ANN SURG ONCOL, V8, P347
[3]   Circumferential resection margin as a prognostic factor in rectal cancer [J].
Bernstein, T. E. ;
Endreseth, B. H. ;
Romundstad, P. ;
Wibe, A. .
BRITISH JOURNAL OF SURGERY, 2009, 96 (11) :1348-1357
[4]  
Bjerkeset T, 1996, EUR J SURG, V162, P643
[5]   Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer [J].
Braendengen, Morten ;
Tveit, Kjell M. ;
Berglund, Ake ;
Birkemeyer, Elke ;
Frykholm, Gunilla ;
Pahlman, Lars ;
Wiig, Johan N. ;
Bystrom, Per ;
Bujko, Krzysztof ;
Glimelius, Bengt .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (22) :3687-3694
[6]   Changes in the management and outcome of rectal cancer over a 10-year period in Oxford [J].
Chambers, W. ;
Hancock, L. ;
McKenzie, R. ;
Buchel, O. ;
Lindsey, I. ;
Cunningham, C. ;
George, B. ;
Mortensen, N. .
COLORECTAL DISEASE, 2011, 13 (09) :1004-1008
[7]   Inadvertent perforation during rectal cancer resection in Norway [J].
Eriksen, MT ;
Wibe, A ;
Syse, A ;
Haffner, J ;
Wiig, JN .
BRITISH JOURNAL OF SURGERY, 2004, 91 (02) :210-216
[8]   Swedish rectal cancer trial: Long lasting benefits from radiotherapy on survival and local recurrence rate [J].
Folkesson, J ;
Birgisson, H ;
Pahlman, L ;
Cedermark, B ;
Glimelius, B ;
Gunnarsson, U .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (24) :5644-5650
[9]   Alternative clinical end points in rectal cancer - are we getting closer? [J].
Glynne-Jones, R. ;
Mawdsley, S. ;
Pearce, T. ;
Buyse, M. .
ANNALS OF ONCOLOGY, 2006, 17 (08) :1239-1248
[10]   Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer [J].
Hurwitz, H ;
Fehrenbacher, L ;
Novotny, W ;
Cartwright, T ;
Hainsworth, J ;
Heim, W ;
Berlin, J ;
Baron, A ;
Griffing, S ;
Holmgren, E ;
Ferrara, N ;
Fyfe, G ;
Rogers, B ;
Ross, R ;
Kabbinavar, F .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2335-2342